Dr. George Georgiou was recently the recipient of a two-year $2 million grant from the Defense Advanced Research Projects Agency (DARPA) to fund a project developing antibodies that bind to their targets more efficiently, ultimately benefiting treatment of cancer and diseases.
George Georgiou
Dr. George Georgiou was recently the recipient of a two-year $2 million grant from the Defense Advanced Research Projects Agency (DARPA) to fund a project developing antibodies that bind to their targets more efficiently, ultimately benefiting treatment of cancer and diseases.
In December 2010, Dr. Georgiou received two grants from the National Institutes of Health (NIH). The first, an NIH R01 $1.5 million four-year grant will fund a project involving the engineering of the enzyme Methioninase for cancer therapy, specifically for treating pediatric tumors. The second grant from NIH will contribute to a project involving the development of antibody diagnostics for filoviruses.
